

South West London
Growth Hormone Commissioning Policy
 Last updated and approved by SWL IMOC: 20 Oct 2021

	Paediatrics (note: if homecare delivery is considered the preferred route, follow SWL adult proposal)	Adults Not for GP prescribing
1st choice	Omnitrope® - Shared care prescribing OR - Homecare delivery For new patients with preference for homecare: Humatrope® * - Homecare delivery only * Humatrope® is the only licensed product for SHOX deficiency and requires reconstitution	Humatrope®* OR Omnitrope® -Homecare delivery only * Humatrope® is the only licensed product for SHOX deficiency and requires reconstitution
2nd choice	Zomacton® * OR Genotropin MiniQuick® OR Genotropin GoQuick® - Shared care prescribing OR - Homecare delivery - * Suitable for patients with true needle phobia	Genotropin (GoQuick)® OR Nutropin AQ® -Homecare delivery only
Exceptional use	Norditropin FlexPro®- Only if fridge storage is a real issue. --Homecare delivery	Zomacton® Only for patients with true needle phobia -Homecare delivery Norditropin FlexPro®- Only if fridge storage is a real issue. -Homecare delivery

Patients currently on a product not listed above should be reviewed with the aim of switching to a product in line with the above policy if considered clinically appropriate.

Rationale:

There are considerable cost saving opportunities for rationalising the number of growth hormone products but still giving patients a choice. LPP recommends that regions should co-ordinate to three products unless there are licensing issues. Above commissioning policy for South West London is informed by:

- Relative cost of growth hormone preparations for London as at May 2021
- Local prescribing agreements (i.e. shared care prescribing agreement for certain products for paediatric patients)
- Practice as a result of the previous SWL Growth hormone Commissioning Policy (July 2018)

NHS Clinical Commissioning Group: SWL CCG

NHS Trusts: Croydon Health Services NHS Trust, Epsom & St Helier University Hospitals NHS Trust, Kingston Hospital NHS Foundation Trust, The Royal Marsden NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust including Queen Mary's Hospital Roehampton

Approved: SWL IMOC (20th Oct 2021)

ADDENDUM 1

(Approved by SWL Integrated Medicines Optimisation Committee on 24 February 2023)

NICE published TA863 (Feb 2023) – Somatrogen for treating growth disturbance in children and young people aged 3 years and over.

This addendum aims to inform clinicians that somatrogen is available as a treatment option as per NICE TA863 and existing local agreements (delivered through homecare; or via shared care prescribing when an approved SWL shared care prescribing guideline is available).

Following a discussion between the responsible clinician and patient about the advantages and disadvantages of each treatment (considering therapeutic need, and likely adherence to treatment), if more than one treatment option is suitable, start with the least expensive drug (taking into account administration costs, dose needed and product price per dose).